Emmanuel S. Antonarakis, MBBCh (Moderator and Course Chair)
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Ashley Ross, MD, PhD
Departments of Urology, Oncology, and Pathology
Johns Hopkins University School of Medicine
Sean P. Collins, MD, PhD
Department of Radiation Medicine
Georgetown University Hospital
1.0 AMA PRA Category 1 Credit™
Mobile + Online on QuantiaMD
Recommended treatment options for prostate cancer vary based on disease severity and life expectancy, with traditional approaches including active surveillance, surgery, radiation therapy, chemotherapy, and androgen deprivation therapy (ADT). Prostate cancer that progresses despite ADT is known as castration-resistant prostate cancer (CRPC). Until recently, the standard of care for CRPC patients was chemotherapy consisting of docetaxel plus prednisone, and median survival was approximately 19 months. Recent FDA approvals have made several powerful, new, life-extending agents available to patients. The current lack of clinical trial evidence regarding the best sequencing of these novel agents means that patient needs and preferences play an important role in treatment selection. This activity will discuss the optimal, evidence-based treatment of patients with advanced prostate cancer, addressing current practice guidelines, shared decision making, and promising clinical trials.
Presented by the Johns Hopkins University School of Medicine in collaboration with MCM Education.
This educational activity is designed to meet the needs of medical oncologists, radiation oncologists, urologists, surgeons, and other clinicians interested and involved in the health care of patients with prostate cancer. There are no prerequisites.
Upon completion of this educational activity, the participant should be able to:
- Summarize recent updates to clinical practice guidelines that reflect significant changes in best practices in the management of advanced prostate cancer.
- Develop evidence-based first- and second-line treatment options for patients with advanced prostate cancer.
- Apply best practices for patient communication and shared decision making to identify and respond to patient information needs and elicit patient preferences when selecting therapies for men with advanced prostate cancer.
- Recall current data about the most promising investigational therapies for metastatic prostate cancer.
POLICY ON SPEAKER AND PROVIDER DISCLOSURE
It is the policy of the Johns Hopkins University School of Medicine (and the Institute for Johns Hopkins Nursing) that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the instructional materials.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:
Emmanuel S. Antonarakis, MBBCh (moderator/course director), has disclosed that he has served as a consultant for ESSA Pharma, Inc., Medivation, Inc., and Merck & Co., Inc.; has received research funding from Janssen Pharmaceuticals, Inc., Astellas Pharma US, Inc., Sanofi, and Dendreon; and has received research funding/patent royalties from Tokai Pharmaceuticals, Inc.
Ashley Ross, MD, PhD, has disclosed that he has served as a consultant for HealthTronics, has received honorarium from Prostate Cancer Academy, has received research funding from Metamark Genetics, Inc., and has an ownership interest in GenomeDx Biosciences Inc.
Sean Collins, MD, PhD, has disclosed that he has served as a consultant/advisor for and has received honorarium from Accuray.
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
Off-Label Product Discussion
No off-label products discussed.
The information you enter here will be used to generate your CME certificate. Please complete all fields to ensure accurate registration.
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
Commercial Support Statements
This activity is supported by educational grants from Sanofi US and Astellas Pharma US.
- * Estimated time to complete this activity: 60 minutes
* Complete the pre-activity assessment.
* Review the educational activity.
* Complete the post-activity assessment and score a minimum of 80% (you are allowed two retakes).
* Complete the evaluation.
* View, print, or save a CME certificate verifying your credit/participation in this activity.
- Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
There is no charge for CME credit.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
© 2017 The Johns Hopkins University. All rights reserved. No part of this enduring material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public.
Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.
CONFIDENTIALITY DISCLAIMER FOR CME CONFERENCE ATTENDEES
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.
I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.
I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.
I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.
I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-502-7983, e-mail: HIPAA@jhmi.edu.
The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is here for training, education and/or observation purposes only.
For CME Questions, please contact the CME Office
(410) 955-2959 or e-mail email@example.com
For CME Certificates, please call (410) 502-9634
Johns Hopkins University School of Medicine Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland 21205-2195
Reviewed & Approved by:
General Counsel, Johns Hopkins Medicine (4/1/03)
(Updated 4/09 and 3/14)